NCT05140720View on ClinicalTrials.gov

Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age

NAUnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

February 28, 2022

Study Completion Date

June 1, 2022

Conditions
Streptococcus PneumoniaVaccine Preventable Disease
Interventions
BIOLOGICAL

PNEUMOSIL®

"Study subjects will be vaccinated PNEUMOSIL® with the primary doses as described below:~Group 1: 3 doses, 4 to 8 week interval Group 2: 2 doses, dose interval \> 1 month Group 3: 2 doses, dose interval \> 2 months"

Sponsors

Lead Sponsor

Vabiotech
All Listed Sponsors
collaborator

Vietstar Biomedical Research

INDUSTRY

lead

Vabiotech

INDUSTRY

NCT05140720 - Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age | Biotech Hunter | Biotech Hunter